After SARS-CoV-2 infects gastrointestinal cells via ACE2 may lead to RAAS dysregulation, exacerbating ionic imbalance and inflammation, affecting cellular metabolic status, flora composition, and cell viability, resulting in increasing gastrointestinal dysfunction in COVID-19 patients (Megyeri et al., 2021). This evidence concerns the gene ACE2 and COVID-19.